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c l i n i c a l  c o n s u l t a t i o n
Risk of venous thromboembolism  
with drospirenone-containing oral contraceptives
Dana a. Brown anD Christine M. Vartan
Purpose. The risk of venous thromboem-
bolism (VTE) with drospirenone-containing 
oral contraceptives (OCs) is reviewed. 
Summary. Increasing attention and media 
have raised awareness and concern about 
whether drospirenone-containing OCs 
increase the risk of VTE. Two studies found 
that when compared with nonuse of OCs, 
use of drospirenone-containing OCs was 
associated with a fourfold to over sixfold 
increased risk of having a thrombotic 
event. One of these studies found an in-
creased risk associated with short-term use 
of drospirenone-containing OCs; however, 
this study was limited by the small number 
of participants taking drospirenone despite 
the large number of study participants. The 
cohort study that found a higher rate of VTE 
among drospirenone users was only able to 
indicate an association between drospire-
none use and VTE, not a cause-and-effect 
relationship. Three studies concluded that 
drospirenone-containing OCs did not ap-
pear to cause an increased risk of VTE. The 
hemostatic studies found no difference in 
the various variables assessed between 
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drospirenone- and desogestrel-containing 
OCs or between cyclic and continuous 
administration of drospirenone-containing 
OCs. These results should be interpreted 
cautiously, as each study had limitations, 
such as not controlling for confounders 
(e.g., recent surgery, immobility, obesity), 
not providing p values to assess homoge-
neity between treatment groups, and not 
providing total numbers of participants or 
specific types of OCs. Patients who receive 
drospirenone-containing OCs should be 
educated regarding the signs and symp-
toms of VTE, along with an appropriate 
action plan. 
Conclusion. The majority of available 
data does not support the conclusion that 
drospirenone-containing OCs pose an 
increased risk of VTE compared with other 
OCs. 
Index terms: Clinical studies; Contracep-
tives, oral; Desogestrel; Dosage schedule; 
Drospirenone; Methodology; Patient infor-
mation; Toxicity; Venous thromboembolism
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The risk of venous thromboembo-lism (VTE) associated with com-bined oral contraceptives (OCs) 
is well recognized. In fact, the World 
Health Organization Collaborative 
Study of Cardiovascular Disease and 
Steroid Hormone Contraception 
found that the risk of VTE among 
patients using OCs is approximately 
threefold to fourfold higher than that 
of patients not taking OCs.1 Since the 
introduction of OCs into the Ameri-
can market in the 1960s, high doses 
of both estrogen (50 mg ethinyl estra-
diol) and progestin (150 mg mestra-
nol) have been linked to VTE.2 The 
safety profile of OCs improved due 
to dose reductions in the estrogen 
component and the development of 
new progestins with favorable safety 
and clinical profiles; these changes 
do not compromise contraceptive 
effectiveness.2-4 Specifically, newer 
progestins have been developed to 
be more receptor selective to more 
closely resemble physiological pro-
gesterone, allowing for increased 
tolerability by minimizing unwanted 
adverse effects, such as acne, hirsut-
ism, and bloating.5 
In the mid-1990s, attention shift-
ed to the risk of VTE associated with 
progestins. Reports of VTE began 
to emerge with the newer, third-
generation progestins gestodene and 
desogestrel. Some data suggested that 
these progestins were associated with 
a higher risk of VTE compared with 
levonorgestrel.6,7 A meta-analysis 
of cohort and case–control studies 
found an overall adjusted odds ratio 
(OR) for VTE of 1.7 (95% confidence 
interval [CI], 1.4–2.0) for third- versus 
second-generation progestins.8 Spe-
cifically, coagulation and fibrinolytic 
pathways seem to be particularly af-
fected by third-generation combined 
OCs.6
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The Clinical Consultation section features 
articles that provide brief advice on how to 
handle specific drug therapy problems. All 
articles are based on a systematic review 
of the literature. The assistance of ASHP’s 
Section of Clinical Specialists and Scientists 
in soliciting Clinical Consultation submis-
sions is acknowledged. Unsolicited submis-
sions are also welcome.
Drospirenone and VTE risk
Unlike other progestins, drospire-
none, a third-generation progestin, is 
a spironolactone analogue. It has an-
timineralocorticoid and antiandro-
genic properties, with a high affinity 
for the progesterone and mineralo-
corticoid receptors and a low affinity 
for androgen receptors.9 A 3-mg dose 
of drospirenone has been found to 
have similar effects to those seen with 
25 mg of spironolactone. Drospire-
none blunts the ability of estrogen 
to stimulate aldosterone release from 
the renin–angiotensin–aldosterone 
system. This reduces water and so-
dium retention and thus minimizes 
breast tenderness, edema, weight 
gain, and elevations in blood pres-
sure.10-12 Its antiandrogenic proper-
ties minimize adverse dermatologi-
cal effects, such as hirsutism, acne, 
and seborrhea.13 The drospirenone 
component of OCs may cause hyper-
kalemia in some women and should 
be avoided in patients with renal 
or adrenal insufficiency or hepatic 
dysfunction. Monitoring of serum 
potassium levels is recommended 
during the first cycle of treatment 
in patients taking medications that 
could raise serum potassium levels 
(e.g., angiotensin-converting-enzyme 
inhibitors, potassium-sparing diuret-
ics, nonsteroidal antiinflammatory 
drugs).14,15 
We conducted a literature search 
using MEDLINE to identify stud-
ies that assessed the risk of VTE 
in women taking drospirenone- 
containing OCs. Various combina-
tions of the following terms were 
used in the search strategy: oral con-
traceptives, hormonal oral contracep-
tives, combined oral contraceptives, 
drospirenone, venous thromboembo-
lism, venous thrombosis, and throm-
boembolism. This article reviews the 
clinical and hemostatic studies in-
vestigating the risk of VTE associated 
with drospirenone-containing OCs. 
Clinical outcomes studies
Seeger et al. Seeger et al.16 con-
ducted a prospective, cohort study to 
determine the risk of VTE in women 
using ethinyl estradiol–drospirenone 
OCs compared with women using 
other types of OCs. The study popu-
lation was selected from a research 
database provided by health plans 
affiliated with UnitedHealthCare 
(Atlanta, GA) and other large em-
ployer groups and limited to females 
age 10–59 years for whom an ethinyl 
estradiol–drospirenone OC was dis-
pensed, who had not taken this type 
of OC before, and who were mem-
bers of their health plan for at least 
6 months (n = 22,429). The com-
parator group—females age 10–59 
years using other types of OCs who 
were members of their health plan 
for at least 6 months—was selected 
based on a propensity score (i.e., 
prediction model) and contained 
twice as many patients as the group 
using ethinyl estradiol–drospirenone 
OCs (n = 44,858). The investigators 
explored insurance claims for infor-
mation on diagnoses, procedures, 
and medications associated with 
VTE. Clinicians, who were blinded 
to information about OC use, evalu-
ated the data to determine if each 
patient had a thromboembolic event. 
The average follow-up time was 7.8 
months (14,081 woman-years) and 
7.5 months (27,575 woman-years) 
in the study and comparator groups, 
respectively. Based on absolute in-
cidence rates, 769 women would 
need to take an ethinyl estradiol–
drospirenone OC for 1 year in order 
for one thromboembolic event to be 
observed, and 714 women would need 
to take another OC for 1 year in order 
for one thromboembolic event to be 
observed. Based on the investigators’ 
calculations for the number needed 
to harm (NNH), OCs would have to 
be prescribed to 9,286 women for one 
more thromboembolic event to occur 
with ethinyl estradiol–drospirenone 
versus a comparator OC.
Based on as-matched results, de-
fined by the investigators as compara-
ble to intent-to-treat, 18 cases of VTE 
occurred in the ethinyl estradiol– 
drospirenone group compared with 
39 in the comparator group. The 
ethinyl estradiol–drospirenone group 
had a VTE incidence of 1.3 per 1000 
woman-years (95% CI, 0.8–2.0) ver-
sus 1.4 per 1000 woman-years (95% 
CI, 1.0–1.9) in the comparator group. 
The rate ratio for VTE between the 
two groups was 0.9 (95% CI, 0.5–1.6). 
Because all of the CIs contained 
the value 1, there may have been a 
decreased risk, no difference in risk, 
or an increased risk of a VTE in the 
ethinyl estradiol–drospirenone group 
compared with the comparator group. 
The as-treated results, based on OC 
exposure time, revealed that in cur-
rent users of an OC, 14 cases of VTE 
occurred in the ethinyl estradiol–
drospirenone group compared with 
30 in the comparator group. The rate 
ratio was 1.0 (95% CI, 0.5–1.9). The 
investigators concluded that the risk 
of VTE did not significantly differ 
between groups. Since the propensity 
score data did not allow investigators 
to assess other confounders (e.g., 
smoking, body mass index [BMI]), 
a validation study was conducted 
to search for possible confounders 
and found no differences between the 
groups that could have affected the re-
sults. However, these latter results were 
not published. Furthermore, the inves-
tigators stated that their results could 
likely be extrapolated to older women 
(e.g., women using drospirenone-
containing hormone replacement 
therapy [HRT]) or women with ex-
tended treatment intervals.
One of the limitations of this 
report was that it lacked p values, 
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which would have signified whether 
there were actual differences between 
the groups in baseline characteristics 
or medical conditions or whether 
the results were due to chance alone. 
Furthermore, the participants for this 
study were identified using medical 
health claims, so individuals without 
insurance were not represented. Also, 
the investigators did not define how 
many patients were taking each of 
the other OCs in the comparator 
group, nor were the comparator OCs 
identified. Although medical records 
were consulted, these records might 
not have been complete or might not 
have contained all relevant informa-
tion on possible risk factors for VTE. 
For example, the investigators did 
not state whether they were able to 
collect information on genetic pre-
disposition, recent surgery, immobil-
ity, or malignancy.17 Although the in-
vestigators searched medical records 
for a random sample of participants 
in order to determine possible con-
founders that could affect the results, 
they did not gather this information 
for all the participants nor did they 
list the findings for those patients 
who were in the random sample. 
Although the investigators indicated 
the absolute incidence rates and 
the NNH, they did not explain 
how they determined those values. 
Also, the NNH was reported for 
all patients, regardless of the OC 
used, instead of for patients using 
only the drospirenone-containing 
OCs. The absolute incidence rates 
indicated a time period of one year, 
though the average study follow-up 
was less than one year. Furthermore, 
due to the study design, only an as-
sociation between ethinyl estradiol–
drospirenone and the risk of throm-
boembolism can be established, not 
a cause-and-effect relationship. Ex-
trapolation of the results to older pa-
tients using drospirenone-containing 
HRT and patients using OCs for ex-
tended intervals cannot be presumed 
from this analysis, as these patients 
were not included in the study.
Dinger et al. (2007). Dinger and 
colleagues2 conducted a prospec-
tive, noninferiority, controlled co-
hort study to compare the risks 
of using drospirenone-containing 
OCs with those of levonorgestrel-
containing and other types of OCs. 
The participants came from seven 
European countries and consisted 
of women who were prescribed an 
OC for the first time or were switch-
ing to another OC and were willing 
to participate in the study. The pri-
mary cardiovascular outcome was 
VTE in women using drospirenone- 
containing OCs versus levonorgestrel-
containing OCs. A sample size of 
50,000 women with a minimum of 
100,000 woman-years of OC use was 
required to provide 90% power and 
exclude a twofold risk of VTE. Data 
from 58,674 participants with a total 
of 142,475 woman-years were evalu-
ated. Drospirenone-containing OC 
users accounted for 28,621 woman-
years. Baseline characteristics of 
each participant were collected via a 
questionnaire. Every six months, the 
women provided follow-up informa-
tion about adverse events via self- 
administered questionnaires. Each 
patient’s physician was contacted to 
verify serious adverse events. The 
number of patients lost to follow-
up was very minimal. Overall, 118 
thromboembolic events occurred, 
with a total of 7 cases of pulmonary 
embolism (PE) in the group receiving 
drospirenone-containing OCs. VTE 
was reported in 26 patients receiving 
drospirenone-containing OCs and 
25 patients taking levonor gestrel- 
containing OCs. The results indi-
cated a VTE incidence of 9.1 per 
10,000 woman-years in patients us-
ing drospirenone-containing OCs 
(95% CI, 5.9–13.3) versus 8.0 per 
10,000 woman-years in patients using 
levonorgestrel-containing OCs (95% 
CI, 5.2–11.7). The crude hazard ratio 
comparing drospirenone-containing 
OCs with levonorgestrel-containing 
OCs was 1.1 (95% CI, 0.7–2.0). After 
adjusting for certain confounders 
(e.g., age, BMI), the resultant ad-
justed hazard ratio for drospirenone- 
containing OCs compared with 
levonorgestrel-containing OCs was 
1.0 (95% CI, 0.6–1.8). The results 
indicated that the twofold risk was 
excluded, and the noninferiority of 
drospirenone-containing OCs for risk 
of VTE was established.
This report had several limita-
tions, including a lack of p values. 
Although the mean age, weight, and 
BMI, as well as certain risk charac-
teristics and preexisting conditions, 
were reported for the study groups, 
no p values were provided to deter-
mine whether there was homoge-
neity between the groups. In fact, 
more patients in the drospirenone- 
containing OC group were obese, thus 
increasing their baseline risk for VTE. 
Also, the investigators did not explic-
itly indicate whether they considered 
or compared genetic predisposition, 
recent surgery, or extended immobil-
ity between the groups.17 The investi-
gators stated that recall bias was not 
a factor in the length of OC use and 
type of OC used, as the data were 
collected from the national prescrip-
tion registry; however, recall bias may 
have occurred, since the women pro-
vided information about their medi-
cal history and history of OC use. 
Further, while the investigators com-
pared drospirenone-containing OCs 
with levonorgestrel-containing OCs 
and other OCs, they did not identify 
the other OCs used or how many pa-
tients were taking them. Based on the 
crude hazard ratio, the investigators 
could not have established nonin-
feriority, since the CI contained the 
value 2.0. Once the hazard ratio 
was adjusted for confounders, the 
twofold risk of VTE with the use of 
drospirenone-containing OCs versus 
levonorgestrel-containing OCs was 
excluded. The involvement of em-
ployees of the study funder, Schering 
AG, which supplies drospirenone-
containing OC products, is un-
known. An independent advisory 
council concluded that there were no 
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major differences between the groups 
regarding the rate of general and 
organ-system-specific serious ad-
verse events, outcome-specific and 
general mortality, and general and 
organ-system-specific cancer. An in-
creased risk was not observed for any 
of the outcomes (e.g., VTE, arrhyth-
mia) evaluated in this study in wom-
en using a drospirenone-containing 
OC. The investigators concluded that 
cardiovascular risks were comparable 
between drospirenone-containing 
OCs and other types of OCs. In ad-
dition, the study was only powered 
to establish the noninferiority of 
drospirenone-containing OCs com-
pared with levonorgestrel-containing 
OCs for the risk of VTE, even though 
multiple regimens were compared.
Lidegaard et al. Another cohort 
study, conducted by Lidegaard et 
al.,18 evaluated the risk of VTE 
among nonpregnant women age 
15–49 years with no history of cancer 
or cardiovascular disease who used 
various formulations of hormonal 
contraception. A total of 10.4 mil-
lion woman-years were observed, 
3,253,131 of which were attributed 
to current OC users. Drospirenone-
containing OC users accounted for 
131,541 woman-years. The primary 
outcome was a first-time thrombotic 
event, including but not limited to 
deep venous thrombosis (DVT) and 
PE. This study found that a first-time 
VTE occurred in 4,213 women, 2,045 
of whom were current OC users. 
Among those using a drospirenone-
containing OC, 103 developed VTE. 
When comparing the risk of devel-
oping a VTE between women using 
drospirenone-containing OCs and 
women classified as nonusers of OCs 
(i.e., those who had never used an 
OC and those who were former us-
ers), the adjusted rate ratio was 4.00 
(95% CI, 3.26–4.91). When compar-
ing the risk of VTE in women who 
used a drospirenone-containing OC 
versus a levonorgestrel-containing 
OC, the adjusted rate ratio was 1.64 
(95% CI, 1.27–2.10). The reported 
rate ratio was adjusted for age, calen-
dar year, education level, and amount 
of time the OC was used. These 
results suggest a higher rate of first-
time VTE among those who used an 
OC containing drospirenone.
This study had several limitations. 
Similar to the previous studies dis-
cussed, p values were not reported, 
and the investigators did not control 
for all confounders (e.g., recent sur-
gery, smoking, genetic predisposi-
tion, BMI, sedentary lifestyle, long-
distance travel, restricted mobility). 
Patient demographics were not re-
ported, and baseline characteristics 
were not analyzed for homogeneity 
between the groups. Although the 
total number of woman-years was 
reported, the total number of women 
in the study and the number of 
women taking each type of hormon-
al contraceptive were not provided. 
Furthermore, the study design only 
allowed the investigators to deter-
mine whether an association existed 
between the use of hormonal contra-
ception and the risk of VTE; a cause-
and-effect relationship could not be 
established from this study, especially 
when considering the confounders 
that were not addressed. The investi-
gators concluded that further studies 
focusing on drospirenone and its 
effect on arterial outcomes must be 
conducted before any clinical recom-
mendations can be made.18
Van Hylckama Vlieg et al. A 
population-based, case–control study 
conducted by Van Hylckama Vlieg et 
al.4 evaluated OC use among patients 
treated in an anticoagulation clinic 
with a first-time DVT or PE. Study 
participants included nonpregnant, 
premenopausal women age 18–49 
years who were at least four weeks 
postpartum at the time VTE oc-
curred and not taking nonoral for-
mulations of contraception. Smok-
ing status and BMI of participants 
were also evaluated. Patients were 
recruited from six anticoagulation 
clinics based on diagnosis of VTE 
and were classified as drospirenone-
containing OC users (n = 1524) or 
nonusers of drospirenone-containing 
OCs (control group, n = 1760). An 
increase in the risk of VTE was as-
sociated with the current use of OCs 
(OR, 5.0; 95% CI, 4.2–5.8). When 
the results were adjusted for age and 
inclusion period, the OR was 6.3 
(95% CI, 2.9–13.7) for patients who 
used a drospirenone-containing OC 
versus nonusers, indicating a more 
than sixfold increase in the risk of 
VTE. When comparing patients us-
ing drospirenone-containing OCs 
with those using levonorgestrel-
containing OCs, the investigators 
found an OR of 1.7 (95% CI, 0.7–3.9) 
for the risk of VTE. Short-term risk 
of VTE, defined as a VTE occurring 
in three months or less after begin-
ning treatment, was also analyzed. 
A comparison between short-term 
use of drospirenone-containing OCs 
and levonorgestrel-containing OCs 
resulted in an OR of 1.9 (95% CI, 
0.2–21.3) regarding the risk of VTE 
among women using a drospirenone-
containing OC. The investigators 
stated that the wide CI was due to 
the small number of women using 
each type of progestin for the study 
period, thereby decreasing the reli-
ability of these findings.
Similar to the previous studies, 
a limitation of this report was the 
lack of p values. While the investiga-
tors obtained patients’ diagnostic 
information from hospital and gen-
eral practitioner records, only those 
patients cared for in one of the six 
participating anticoagulation clin-
ics were included in this study. The 
investigators selected the majority 
(59.5%) of the participants in the 
control group through the use of 
random-digit telephone dialing. This 
constitutes a selection bias, since 
only those people who were able to 
be reached by telephone were consid-
ered for participation. Furthermore, 
the investigators did not provide any 
specific information about what time 
of day they called each telephone 
number, the use of voicemail, or the 
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number of attempts. Of those people 
reached via random-digit telephone 
dialing, 1048 were chosen to serve as 
controls; however, the investigators 
did not indicate how each person was 
selected. Recall bias may have also 
been a factor, since patients had to 
complete a questionnaire about risk 
factors and OC use. Furthermore, 
the study design only allowed the 
investigators to determine that an 
association existed between the use 
of OCs and the risk of VTE, not a 
cause-and-effect relationship. While 
certain risk factors were assessed, the 
demographics were not compared 
to determine homogeneity between 
groups. Additionally, the investiga-
tors did not state whether they asked 
patients or participants to report any 
malignancies or recent surgeries. Few 
patients in this study actually took 
a drospirenone-containing OC (19 
in the VTE group and 14 in the 
control group), despite the large 
number of participants. Also, the 
height and weight used to calculate 
BMI were reported by the patients 
themselves; this was a potential 
source of bias. Furthermore, the 
CI contained the value of 1 in the 
analyses comparing women using 
a drospirenone-containing OC 
with those using a levonorgestrel-
containing OC and those using both 
of these OCs for the short term, 
suggesting a decreased risk, no dif-
ference in risk, or an increased risk 
of VTE. However, the small number 
of patients using OCs for this period 
of time may have affected the results. 
Also, the results showed a wide CI 
for the risk of VTE in those women 
using drospirenone-containing OCs 
compared with nonusers (95% CI, 
2.9–13.7), indicating that the sample 
may not have truly represented 
the population. Although the total 
number of women in this study was 
reported, the number of patients 
taking each type of hormonal con-
traception was not indicated. The 
investigators concluded that with 
regard to VTE risk, the safest OC is 
one that contains levonorgestrel and 
a low dose of estrogen. 
Dinger et al. (2010). A community-
based, case–control study was con-
ducted by Dinger et al.19 to assess 
the incidence of VTE in OC users 
compared with matched controls. 
Women age 15–49 years who were 
diagnosed with VTE were identified 
through communication with 250 
health care practitioners in all federal 
states of Germany. A questionnaire 
was administered to assess patients’ 
various risk factors for VTE (e.g., 
use of OCs, body weight or height, 
smoking, family and personal his-
tory of VTE, varicose veins, immo-
bility, pregnancy, history of surgery 
or trauma, genetic risk factors). Four 
community-based controls were 
randomly identified for each woman 
with VTE. The controls lived in the 
same town as the women with VTE 
and were contacted by trained inter-
viewers. A total of 3400 patients were 
analyzed (680 women with VTE and 
2720 controls). Twenty-five cases of 
VTE were identified among users of 
drospirenone-containing OCs, com-
pared with 60 cases in women taking 
low-dose levonorgestrel-containing 
OCs and 35 cases in users of dienogest-
containing OCs. The overall crude 
OR associated with current OC use 
was 1.9 (95% CI, 1.5–2.5), and the 
adjusted OR was 2.3 (95% CI, 1.7–
3.0). When drospirenone-containing 
OCs were compared with low-dose 
levonorgestrel-containing OCs, the 
crude OR was 1.0 (95% CI, 0.6–1.6), 
and the adjusted OR was 1.0 (95% 
CI, 0.6–1.8). The investigators con-
cluded that the use of drospirenone-
containing OCs was not associated 
with a higher risk of VTE.
The investigators controlled for 
many confounders, though some 
were not explicitly discussed (e.g., 
chronic diseases, concomitant medi-
cations). Limitations of this study 
included the random selection of 
patients from only 250 health care 
practitioners in Germany and the 
possibility of recall bias due to the 
retrospective collection of patient 
data. In addition, p values were not 
provided for the assessment of base-
line characteristics. Furthermore, 
evaluating the risk of VTE associated 
with drospirenone-containing OCs 
was a secondary objective of the study.
International Active Surveil-
lance Study of Women Taking Oral 
Contraceptives. This currently ongo-
ing, prospective, noninterventional, 
multinational, cohort, noninferiority 
study is assessing the safety of the 
24-day combination of drospirenone 
3 mg and ethinyl estradiol 20 mg 
as part of a Phase IV study for the 
Food and Drug Administration.20 
The study began in the United States 
in August 2005 and in Europe in 
the fall of 2008. The follow-up pe-
riod will be three to five years in the 
United States and two to four years in 
Europe. Participants include all 
women beginning therapy with a 
new OC (either for the first time or 
switching to a different product) 
who are willing to join the study. The 
investigators estimate that there will 
be approximately 80,000 participants 
with an estimated 220,000 woman-
years, which would give the study 
90% power to exclude a twofold risk 
of VTE. The primary outcome is 
the hazard ratio of VTE (i.e., DVT 
and PE) associated with the 24-day 
regimen of drospirenone–ethinyl 
estradiol compared with other OCs. 
Follow-up questionnaires will be 
completed at six-month intervals, 
and serious adverse events will be 
confirmed through the patients’ phy-
sician. This study is funded by Bayer 
Schering Pharma AG.
Hemostatic outcomes studies
Klipping and Marr. An open-
label, randomized controlled study 
involving healthy women age 18–35 
years was conducted by Klipping and 
Marr21 to compare various outcomes 
in participants taking either ethinyl 
estradiol 20 mg–drospirenone 3 mg 
(24 active pills) or ethinyl estradiol 
20 mg–desogestrel 150 mg (21 active 
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pills). Women up to age 30 years who 
were smokers were also allowed to 
participate in the study. The exclu-
sion criteria were extensive; some 
included pregnancy and lactation, 
a BMI of >30 kg/m2, uncontrolled 
thyroid conditions, diabetes, use of 
medications that affect the kinetic 
profile of OCs, use of an OC within 
two cycles before initiating the OC 
used during the study, uncontrolled 
hypertension, and malignant or 
premalignant tumors. Hemostatic 
outcomes, as secondary objectives, 
were assessed in women using these 
two types of OCs. 
The full analysis set, which in-
cluded patients who used at least 
1 tablet of their randomized OC 
and with at least one observation, 
included a total of 29 women in the 
drospirenone-containing OC group 
and 30 women in the desogestrel-
containing OC group. The results 
indicated an increase in prothrombin 
fragments 1 and 2 and in D-dimer 
levels. The mean rise in levels of 
prothrombin fragments 1 and 2 was 
lower in the drospirenone-containing 
OC group; however, the mean in-
crease in D-dimer levels was higher 
in the drospirenone-containing OC 
group. The investigators stated that 
the mean difference between the 
groups was not significant for either 
prothrombin 1 and 2 levels (–0.06 
nmol/L; 95% CI, –0.18 to 0.06) or D-
dimer levels (15.26 ng/mL; 95% CI, 
–45.91 to 76.43). The mean absolute 
difference in procoagulatory factors 
(i.e., factors VII and VIII and fibrino-
gen) in the drospirenone-containing 
OC group was higher than that in the 
desogestrel-containing OC group. 
For the anticoagulation variables, 
the mean absolute change for users 
of drospirenone-containing OCs 
suggested less of a decrease in anti-
thrombin activity but demonstrated 
a greater increase in protein C activ-
ity. The drospirenone-containing OC 
group had a greater decrease in mean 
absolute change for free and total 
protein S levels. An increase in the 
profibrinolytic values (e.g., plasmin-
ogen, plasmin–antiplasmin complex) 
was observed in both groups; how-
ever, the increase was greater in the 
drospirenone-containing OC group. 
The antifibrinolytic measure (i.e., 
plasminogen activator inhibitor-1 
[PAI-1] antigen) decreased for both 
groups, though there was a greater 
decrease in the mean absolute change 
in the desogestrel-containing OC 
group. The investigators concluded 
that the drospirenone-containing 
OC and the desogestrel-containing 
OC were associated with similar he-
mostatic changes.
A limitation of this report was the 
lack of p values for both the base-
line characteristics and the results. 
Also, the investigators did not assess 
whether any of the women had un-
dergone recent surgery, which is a 
risk factor for VTE17 and may have 
affected the hemostatic changes. In 
addition, the study did not have 
adequate statistical power to detect 
a difference in the hemostatic out-
comes, since these were secondary 
outcomes. Based on these factors, it 
is not clear whether the hemostatic 
changes between the two groups 
were similar. Furthermore, the 
results from this study cannot be 
extrapolated to all patients taking 
drospirenone-containing OCs due 
to the extensive exclusion criteria 
and because nearly all the study par-
ticipants were Caucasian. 
Kluft et al. An open-label, ran-
domized, prospective study was 
conducted by Kluft et al.22 to com-
pare the hemostatic effects of dro-
spirenone 3 mg–ethinyl estradiol 
30 mg, drospirenone 3 mg–ethinyl 
estradiol 20 mg, and desogestrel 150 
mg–ethinyl estradiol 30 mg. The study 
was conducted from October 1992 
through July 1993 and included 
healthy women age 18–35 years from 
one outpatient clinic who were either 
new users of combined OCs or were 
changing from their current OC. 
Smokers age 30 years or younger who 
smoked no more than 10 cigarettes 
daily were included in the study. The 
criteria for exclusion “were similar 
to the known contraindications for 
combined OC use” and included the 
use of “coagulation-relevant prepara-
tions,” a family history of coagulation 
disorders, use of a parenteral depot 
contraceptive within the previous six 
months, “specified concomitant pa-
thology,” unclassified genital bleed-
ing, and a history of migraines with 
menstruation. 
Seventy-five women were ran-
domized to one of the three treat-
ment groups (25 per group). Par-
ticipants underwent a one-cycle 
washout period, a cycle in which no 
treatment was given, six cycles of 
treatment, and a 28-day follow-up 
period with no treatment. Baseline 
body weight values were higher in 
the drospirenone–ethinyl estra-
diol 20-mg group compared with the 
desogestrel–ethinyl estradiol 30-mg 
and drospirenone–ethinyl estradiol 
30-mg groups (by 4.5 and 4.6 kg, re-
spectively). Procoagulatory, antico-
agulatory, fibrinolytic, antifibrino-
lytic, and global clotting tests were 
conducted at baseline; at cycles 1, 3, 
and 6; and twice during the follow-
up period. The results demonstrated 
that each of the procoagulatory mea-
sures (i.e., platelet count, fibrinogen, 
factor VII, and thrombin–antithrom-
bin complex) increased; however, the 
only significant increase among the 
groups from baseline to cycle 6 was 
for fibrinogen (p = 0.0329). Further 
analysis with a two-sided Wilcoxon 
test indicated a significant increase in 
fibrinogen for drospirenone–ethinyl 
estradiol 20-mg when compared with 
desogestrel–ethinyl estradiol 30-mg 
(p = 0.0078). Regarding anticoagula-
tory measures, antithrombin and 
protein C antigen nonsignificantly 
increased among all three groups 
from baseline to cycle 6. Furthermore, 
reduced protein S antigen and activity 
levels were noted in all three groups. 
Use of a two-sided Kruskal–Wallis 
test revealed a significant change in 
protein S activity among the groups 
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(p = 0.0183). Additional analysis with 
a two-sided Wilcoxon test indicated a 
significant change in protein S activ-
ity between the drospirenone–ethinyl 
estradiol 20-mg and drospirenone–
ethinyl estradiol 30-mg groups 
(p = 0.0198) and between the dro-
spirenone–ethinyl estradiol 20-mg 
and desogestrel–ethinyl estradiol 
30-mg groups (p = 0.0111). The dif-
ferences in the profibrinolytic, anti-
fibrinolytic, and global clotting test 
results and in D-dimer levels among 
the groups were not significant. The 
investigators stated that the results 
signified similar changes in the he-
mostatic variables among all three 
groups and concluded that the use of 
drospirenone–ethinyl estradiol 20 mg 
yielded changes in hemostatic values 
that were not as marked as those seen 
with the other two regimens.
One of the limitations of this re-
port is that the investigators did not 
provide p values for the differences 
between the demographic char-
acteristics and baseline laboratory 
data, and there was no indication 
that the statistical tests were selected 
a priori. Also, the investigators did 
not explicitly state the contraindica-
tions for OC use that were part of 
the exclusion criteria. Furthermore, 
the data derived from this study ap-
ply to women receiving 21 days of 
drospirenone–ethinyl estradiol 20 mg 
and are not necessarily indicative of 
findings in women taking 24 days of 
active tablets.
Machado et al. In an open- 
label, prospective, randomized 
study, Machado et al.23 assessed the 
effects of ethinyl estradiol 30 mg–
drospirenone 3 mg given continu-
ously (daily administration for 168 
days) and cyclically (six 28-day cycles 
with a one-week hormone-free pe-
riod) on metabolic and coagulation 
variables. Participants included sexu-
ally active women age 18–35 years 
desiring to use contraception who 
were not receiving hormonal con-
traception for at least two months 
before study entry or who had an 
intrauterine contraceptive device. 
The study also required participants 
to have a BMI of 19–30 kg/m2, at least 
eight years of education, and the abil-
ity to comprehend written and oral 
instructions. Exclusion criteria in-
cluded pregnancy, abnormal findings 
on a cervicovaginal colposcopy, use 
of drugs that may interact with OCs 
(e.g., barbiturates, carbamazepine, 
rifampicin), and personal history of 
conditions such as breast or genital 
cancer, cardiovascular disease, VTE 
or arterial thromboembolism, diabe-
tes, alcoholism, acute or chronic liver 
disease, and arterial hypertension. 
A total of 78 women were included, 
with 39 allocated to each treatment 
group.
When assessing coagulation vari-
ables, both thrombin time and ac-
tivated partial thromboplastin time 
levels were reduced significantly 
from baseline in both groups; how-
ever, no significant difference was 
noted between treatment groups. 
No significant changes in fibrinogen, 
antithrombin III, PAI-1, protein C 
antigen, or D-dimer levels were ob-
served in baseline and intergroup 
comparisons. The mean free protein 
S antigen level was significantly lower 
in the cyclic treatment group com-
pared with the continuous-treatment 
group (p = 0.0232). The investigators 
concluded that comparable changes 
with no negative effects could be 
expected with cyclic and continuous 
administration of drospirenone-
containing OCs.
The findings from this study 
should be interpreted cautiously. 
Because assessment of the hemo-
static variables was a secondary out-
come, the study was not adequately 
designed or powered to determine 
a difference in these values. In ad-
dition, the investigators mentioned 
that three patients tested positive for 
the activated protein C resistance 
test, “constituting a criterion for ex-
clusion.” Interestingly, coagulation 
disorders were not listed as part of 
the exclusion criteria. The external 
validity of this study is somewhat 
limited by the numerous diseases that 
were excluded. Thus, the data may not 
be extrapolated to patients with dia-
betes or cardiovascular disease.
Discussion
A review of the current literature 
revealed that data are conflicting 
regarding the risk of VTE associ-
ated with drospirenone-containing 
OCs. Two studies found that when 
compared with nonuse of OCs, use 
of drospirenone-containing OCs 
was associated with a fourfold to 
over sixfold increased risk of having 
a thrombotic event.4,18 In addition, 
when compared with OCs contain-
ing levonorgestrel, the adjusted rate 
ratios suggested an almost twofold 
risk of VTE with drospirenone-
containing OCs. One of these studies 
found an increased risk associated 
with short-term use (three months 
or less) of drospirenone-containing 
OCs.4 However, this study was lim-
ited by the small number of partici-
pants who were taking drospirenone 
(n = 19) despite the large number of 
study participants (n = 3284). 
Three studies did not find an 
increased risk of VTE with drospi-
renone.2,16,19 One of these studies 
assessed medical health claims, lim-
iting the patient population evalu-
ated.16 In addition, the investigators 
did not explain how they calculated 
the reported NNH. Based on study 
design, only an association between 
VTE and drospirenone use could be 
established, not a cause-and-effect 
relationship. In another study, the 
investigators stated that noninferi-
ority was established; however, this 
statement was based on an adjusted 
hazard ratio, as the crude hazard ra-
tio did not establish noninferiority.2 
Lastly, in a case–control study, the 
use of drospirenone-containing OCs 
was not found to increase the risk of 
VTE.19 However, the data should be 
interpreted cautiously, as assessment 
of drospirenone-containing OCs was 
a secondary objective of the study.
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Data from two of the hemostatic 
outcomes studies suggested that 
changes in hemostatic variables 
were similar between drospirenone- 
and desogestrel-containing OCs.21,22 
Comparable findings were noted in 
a study that assessed continuous ver-
sus cyclic drospirenone-containing 
OCs.23 The findings from two of the 
studies were limited given that the 
results were secondary outcomes; 
thus, the studies were not powered to 
determine a statistical difference.21,23 
Moreover, these studies included 
extensive exclusion criteria, and one 
study included predominantly Cau-
casian females, reducing its external 
validity.21 Based on these limita-
tions, it is uncertain if the changes 
in hemostatic variables would be 
similar between drospirenone- and 
desogestrel-containing OCs as well 
as between cyclic and continuous 
drospirenone-containing OCs.
Taken collectively, the data from 
these outcomes studies should be 
interpreted cautiously given their 
numerous limitations. Most of the 
study reports did not include p 
values, which are imperative for 
determination of  homogeneity 
among treatment groups. In addi-
tion, though some confounders were 
controlled for, other known risk fac-
tors for VTE, such as recent surgery, 
immobility, and obesity, were not.17 
Some of the studies did not provide 
total numbers of participants and 
types of other combined OCs used. 
Studies that incorporated question-
naires were subject to recall bias, 
though investigators attempted to 
minimize this. 
Given the findings from the 
medical literature, it appears that 
drospirenone-containing OCs re-
main a viable method of oral con-
traception for some women. The 
provision of adequate patient coun-
seling is important to help patients 
identify signs and symptoms of VTE. 
Patients should also be encouraged 
to seek immediate help in the event 
of a suspected adverse effect. Patients 
prone to hyperkalemia (i.e., those 
with hepatic insufficiency, with ad-
renal insufficiency, or taking medica-
tions that can raise potassium levels) 
should be identified to help avoid 




The majority of available data 
does not support the conclusion that 
drospirenone-containing OCs pose 
an increased risk of VTE compared 
with other OCs.
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